190 related articles for article (PubMed ID: 22527669)
1. A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA.
Masson-Lecomte A; Guy L; Pedron P; Bruyere F; Rouprêt M; Nsabimbona B; Dahan M; Hoffman P; Salomon L; Vordos D; Hoznek A; Le Corvoisier P; Morel P; Abbou C; de la Taille A
World J Urol; 2013 Apr; 31(2):339-43. PubMed ID: 22527669
[TBL] [Abstract][Full Text] [Related]
2. Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer.
Raddin RS; Walko CM; Whang YE
Anticancer Drugs; 2011 Mar; 22(3):299-302. PubMed ID: 21360851
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist.
Ezaki T; Kosaka T; Mizuno R; Shinojima T; Kikuchi E; Miyajima A; Oya M
Cancer Chemother Pharmacol; 2015 Aug; 76(2):301-6. PubMed ID: 26055219
[TBL] [Abstract][Full Text] [Related]
4. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
Crawford ED; Tombal B; Keane T; Boccardo F; Miller K; Shore N; Moul JW; Damber JE; Collette L; Persson BE
Scand J Urol; 2018; 52(5-6):349-357. PubMed ID: 30624128
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
6. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
7. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
8. Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.
Ulmert D; Vickers AJ; Scher HI; Becker C; Iversen P; Frankel D; Jensen JK; Olesen TK; Lilja H
Clin Chem Lab Med; 2012 Nov; 50(11):1993-8. PubMed ID: 22718641
[TBL] [Abstract][Full Text] [Related]
9. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
10. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
11. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
[TBL] [Abstract][Full Text] [Related]
13. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
Damber JE; Tammela TL; Iversen P; Abrahamsson PA; Boccon-Gibod L; Olesen TK; van der Meulen E; Persson BE
Urology; 2012 Jul; 80(1):174-80. PubMed ID: 22748873
[TBL] [Abstract][Full Text] [Related]
14. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
Pedraza R; Kwart AM
Urology; 2003 Apr; 61(4):770-3. PubMed ID: 12670563
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL.
Kashiwabara T; Suda S
BMC Cancer; 2018 May; 18(1):619. PubMed ID: 29855278
[TBL] [Abstract][Full Text] [Related]
16. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
17. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
18. [Correlation of change in prostate-specific antigen and testosterone following withdrawal of androgen ablation after combination of radiation and hormone therapy].
Hashine K; Numata K; Azuma K; Sumiyoshi Y
Nihon Hinyokika Gakkai Zasshi; 2005 Nov; 96(7):678-84. PubMed ID: 16363653
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.
Bryce AH; Chen YH; Liu G; Carducci MA; Jarrard DM; Garcia JA; Dreicer R; Hussain M; Eisenberger MA; Plimack ER; Vogelzang NJ; DiPaola RS; Harshman L; Sweeney CJ
Eur Urol Oncol; 2020 Dec; 3(6):717-724. PubMed ID: 32807727
[TBL] [Abstract][Full Text] [Related]
20. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
